Maze Therapeutics (NASDAQ:MAZE) Raised to Strong-Buy at Citigroup

Maze Therapeutics (NASDAQ:MAZE) was upgraded by stock analysts at Citigroup to a “strong-buy” rating in a report issued on Wednesday, Zacks reports.

Several other brokerages have also recently issued reports on MAZE. BTIG Research reissued a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a research report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $110.00 price objective on shares of Maze Therapeutics in a research report on Thursday. Wall Street Zen cut shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Finally, Wedbush reiterated an “outperform” rating and set a $48.00 price objective on shares of Maze Therapeutics in a research report on Wednesday. Four investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $63.40.

Maze Therapeutics Stock Performance

Shares of MAZE stock opened at $26.21 on Wednesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. The company has a market capitalization of $1.46 billion, a price-to-earnings ratio of -10.40 and a beta of 2.17. Maze Therapeutics has a one year low of $21.95 and a one year high of $53.65. The company’s 50-day moving average is $27.16 and its 200 day moving average is $29.04.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.76). Sell-side analysts expect that Maze Therapeutics will post -2.72 EPS for the current fiscal year.

Insider Activity at Maze Therapeutics

In other news, CEO Jason Coloma sold 11,411 shares of the company’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total value of $296,800.11. Following the transaction, the chief executive officer directly owned 27,362 shares in the company, valued at approximately $711,685.62. This represents a 29.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CMO Harold Bernstein sold 9,705 shares of the firm’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $26.22, for a total transaction of $254,465.10. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 191,459 shares of company stock valued at $5,263,539 over the last ninety days. Company insiders own 5.30% of the company’s stock.

Institutional Trading of Maze Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada boosted its position in Maze Therapeutics by 214.1% during the first quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock valued at $61,000 after purchasing an additional 1,383 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Maze Therapeutics in the second quarter worth about $48,000. Quantbot Technologies LP purchased a new stake in shares of Maze Therapeutics during the second quarter valued at about $80,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Maze Therapeutics during the fourth quarter valued at about $145,000. Finally, IFP Advisors Inc bought a new stake in shares of Maze Therapeutics in the 4th quarter valued at about $146,000.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.